Status:
TERMINATED
QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
Lead Sponsor:
NantCell, Inc.
Conditions:
Advanced Squamous Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This is a global, multicenter, 2-part, open-label phase 1b and single-arm phase 2 study designed to evaluate the safety and efficacy of AMG 479 in combination with paclitaxel and carboplatin for the f...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed advanced squamous NSCLC
- Measurable disease as defined per modified RECIST criteria
- ECOG performance status of 0 or 1
- ≥18 years old
- Adequate glycemic function, for subjects with known diabetes
Exclusion
- Untreated or symptomatic central nervous system (CNS) metastases
- Prior anti-cancer therapy as follows: Any prior chemotherapy for squamous NSCLC; Any prior adjuvant or neoadjuvant chemotherapy for squamous NSCLC; Any prior chemoradiation for squamous NSCLC; Central (chest) radiation therapy ≤ 28 days prior to enrollment, radiation therapy for peripheral lesions≤14 days prior to enrollment for squamous NSCLC
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00807612
Start Date
January 1 2009
End Date
August 1 2010
Last Update
September 25 2024
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Fayetteville, Arkansas, United States, 72703
2
Research Site
Fayetteville, Arkansas, United States
3
Research Site
Fort Wayne, Indiana, United States, 46845
4
Research Site
Fort Wayne, Indiana, United States